Reimbursement Consulting for Infectious Disease Practices

Health insurance reimbursement generally follows a chain from eligibility and coverage review to authorization, documentation, coding, claim submission, adjudication, payment, and follow-up. The payer applies benefits, contracts, coding rules, and medical or pharmacy benefit requirements to determine payment. For infectious disease practices, reimbursement may involve E/M services, drug charges, infusion administration, OPAT, and hospital or coverage agreements.

Reimbursement consulting can examine the complete path from referral to final payment. For an infectious disease practice, that may include documentation, coding, eligibility, prior authorization, drug acquisition, infusion billing, claims submission, denials, underpayments, aging A/R, payer contracts, and hospital coverage arrangements. The goal is to clarify where revenue is delayed, lost, or left uncollected and identify practical areas for improvement.

Infectious disease practices may deliver cognitive services while also managing infusion, OPAT, drug acquisition, administration charges, specialty medications, and different payer benefit structures. Revenue can be affected by documentation, coding, authorization, medical-versus-pharmacy benefit decisions, contract terms, and claim follow-up. A focused review helps connect these operational details rather than evaluating each revenue stream in isolation.

Yes. Revenue leakage analysis can examine reporting by payer, service line, and provider to identify missing or delayed revenue. Common areas include under-leveled visits, uncaptured drug or administration charges, documentation gaps, contract payment issues, unpursued balances, and claims that stall in the cycle. The analysis traces the issue back to its likely source so the practice can address the underlying workflow.

Payment reconciliation compares reimbursement received with the amount expected under applicable payer terms for drug, administration, and E/M claims. The review can identify short-pays, incorrect fee schedule application, unit mismatches, NDC mismatches, or other payment discrepancies. Findings can then support disputes and tracking so the practice has a clearer view of outstanding recovery opportunities.

Denial reduction begins by organizing denials according to root cause rather than treating every rejected claim the same way. Relevant categories may include drug and administration coding, missing authorization, medical-versus-pharmacy benefit confusion, and under-documented consults. Reviewing the findings with clinical, coding, and front-office teams helps improve the process that created the denial and supports more targeted payer appeals.

Yes. Consulting can review the operational and financial workflow for an infusion suite or OPAT program, including eligibility, benefit determination, prior authorization, drug acquisition, documentation, coding, administration billing, claims submission, and payment follow-up. This helps practices understand how the program fits into the broader revenue cycle and where controls may be needed before services are delivered.

Useful information may include payer and service-line reporting, claim and denial patterns, payment records, aging A/R, workflow documents, contract terms, authorization procedures, and details about infusion or OPAT operations. Practices can also identify questions about coding, documentation, drug billing, or coverage agreements. The more clearly the current workflow and practice-specific numbers are defined, the easier it is to evaluate possible gaps.